Germany
Japan
United Kingdom
China
Recombinant Anti-erbB-2 (Her-2/neu) (Clone 4D5-8 (trastuzumab))
| Applications | ELISA, FC, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Antibodies
View as table Download
Recombinant Anti-TNF alpha (Clone cA2 (Infliximab))
| Applications | ELISA, FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-TRP-1, gp75 (Clone TA99)
| Applications | ELISA, FC, IF, IHC, IP, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Human Ephrin Type A receptor 2 (Clone 1C1)
| Applications | ELISA, FC, IF, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
USD 523.00
2 Weeks
USD 523.00
2 Weeks
Recombinant Anti-alpha 5 beta 1 Integrin (Clone M200 (Volociximab))
| Applications | ELISA, FC, IF, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-CD4 (Clone CE9.1 (Clenoliximab))
| Applications | ELISA, FC, IHC |
| Reactivities | Chimpanzee, Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-alpha-gal epitope (Clone m86)
| Applications | ELISA, FC |
| Conjugation | Unconjugated |
| Modifications | This chimeric human antibody was made using the variable domain sequences of the original Mouse IgM format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-ED-B domain of fibronectin (Clone A2)
| Applications | ELISA, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-ED-B domain of fibronectin (Clone G4)
| Applications | ELISA, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Bet v 1 (Clone M0418)
| Applications | ELISA |
| Conjugation | Unconjugated |
| Modifications | This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Phl p 1 (Clone Clone 25)
| Applications | ELISA, WB |
| Reactivities | Rat |
| Conjugation | Unconjugated |
| Modifications | This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-VEGF (Clone Bevacizumab)
| Applications | ELISA, FC, IP, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-TNF alpha (Clone D2E7 (Adalimumab))
| Applications | ELISA, IF, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-RSV (Clone RSHZ19 (Felvizumab))
| Applications | ELISA |
| Reactivities | Respiratory Syncytial Virus |
| Conjugation | Unconjugated |
Recombinant Anti-CD80 (Clone IDEC-114 (Galiximab))
| Applications | ELISA, FC, IHC, IP, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-IL-6 receptor (Clone rhPM-1 (Tocilizumab))
| Applications | ELISA |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-GM2 ganglioside (Clone L55-81)
| Applications | ELISA, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-CD40 (Clone 5D12)
| Applications | ELISA, FC, IHC, IP |
| Reactivities | Human, Monkey, Cynomolgus |
| Conjugation | Unconjugated |
Recombinant Anti-Fas (Clone R-125224)
| Applications | ELISA, FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
USD 523.00
2 Weeks
Recombinant Anti-EGFR (Clone 2F8 (Zalutumumab; HuMax-EGFR))
| Applications | ELISA, FC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Recombinant Anti-COVID-19 & SARS-CoV S glycoprotein (Clone CR3022)
| Applications | ELISA, IF |
| Conjugation | Unconjugated |
Recombinant Anti-COVID-19 & SARS-CoV S glycoprotein (Clone CR3022)
| Applications | ELISA, IF |
| Conjugation | Unconjugated |
| Modifications | This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-COVID-19 & SARS-CoV S glycoprotein (Clone CR3022)
| Applications | ELISA, IF |
| Conjugation | Unconjugated |
| Modifications | This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-CD80 (Clone 16C10)
| Applications | ELISA |
| Reactivities | Human |
| Conjugation | Unconjugated |
USD 523.00
2 Weeks
Recombinant Anti-Covid-19 & SARS-CoV Nucleoprotein (Clone CR3018 (03-018))
| Applications | ELISA, IF |
| Reactivities | SARS-CoV |
| Conjugation | Unconjugated |
USD 675.00
2 Weeks
Recombinant Anti-Covid-19 & SARS-CoV Nucleoprotein (Clone CR3018 (03-018))
| Applications | ELISA, IF |
| Reactivities | SARS-CoV |
| Conjugation | Unconjugated |
| Modifications | This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
USD 675.00
2 Weeks
Recombinant Anti-Covid-19 & SARS-CoV Nucleoprotein (Clone CR3018 (03-018))
| Applications | ELISA, IF |
| Reactivities | SARS-CoV |
| Conjugation | Unconjugated |
| Modifications | This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
USD 523.00
2 Weeks
Recombinant Anti-Covid-19 & SARS-CoV Nucleoprotein (Clone CR3009 (03-009))
| Applications | ELISA, IF |
| Reactivities | SARS-CoV |
| Conjugation | Unconjugated |
USD 675.00
2 Weeks
Recombinant Anti-Covid-19 & SARS-CoV Nucleoprotein (Clone CR3009 (03-009))
| Applications | ELISA, IF |
| Reactivities | SARS-CoV |
| Conjugation | Unconjugated |
| Modifications | This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
USD 675.00
2 Weeks
Recombinant Anti-Covid-19 & SARS-CoV Nucleoprotein (Clone CR3009 (03-009))
| Applications | ELISA, IF |
| Reactivities | SARS-CoV |
| Conjugation | Unconjugated |
| Modifications | This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Spike protein (RBD) (Clone Sb#14)
| Applications | ELISA, Inhib |
| Conjugation | Unconjugated |
| Modifications | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Spike protein (RBD) (Clone Sb#14)
| Applications | ELISA, Inhib |
| Conjugation | Unconjugated |
| Modifications | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Spike protein (RBD) (Clone Sb#14)
| Applications | ELISA, Inhib |
| Conjugation | Unconjugated |
| Modifications | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Spike protein (RBD) (Clone Sb#16)
| Applications | ELISA, Inhib |
| Conjugation | Unconjugated |
| Modifications | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Spike protein (RBD) (Clone Sb#16)
| Applications | ELISA, Inhib |
| Conjugation | Unconjugated |
| Modifications | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Spike protein (RBD) (Clone Sb#16)
| Applications | ELISA, Inhib |
| Conjugation | Unconjugated |
| Modifications | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Spike protein (RBD) (Clone Sb#42)
| Applications | ELISA, Inhib |
| Conjugation | Unconjugated |
| Modifications | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Spike protein (RBD) (Clone Sb#42)
| Applications | ELISA, Inhib |
| Conjugation | Unconjugated |
| Modifications | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Spike protein (RBD) (Clone Sb#42)
| Applications | ELISA, Inhib |
| Conjugation | Unconjugated |
| Modifications | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Spike protein (RBD) (Clone Sb#45)
| Applications | ELISA, Inhib |
| Conjugation | Unconjugated |
| Modifications | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Spike protein (RBD) (Clone Sb#45)
| Applications | ELISA, Inhib |
| Conjugation | Unconjugated |
| Modifications | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Spike protein (RBD) (Clone Sb#45)
| Applications | ELISA, Inhib |
| Conjugation | Unconjugated |
| Modifications | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |
Active filters
Category
- Antibodies
Applications
- ELISA
Antibody Hosts
- Human
Clonalities
- Monoclonal
Conjugates
- Unconjugated
Assay Types
- Indirect
Filter by
Target Symbol
Reactivities
Isotypes
Modifications
- This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. (12)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (7)
- This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (6)
- This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (4)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgM format, for improved compatibility with existing reagents, assays and techniques. (1)